tylvalosin
Description
3-acetyl-4''-isovaleryltylosin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 6441094 |
CHEMBL ID | 2103834 |
MeSH ID | M0541553 |
Synonyms (31)
Synonym |
---|
einecs 264-132-2 |
D10032 |
tylvalosin (usan/inn) |
unii-9t02s42wqo |
aiv-tylosin |
(4r,5s,6s,7r,9r,11e,13e,15r,16r)-15-(((6-deoxy-2,3-di-o-methyl-beta-d-allopyranosyl)oxy)methyl)-6-((3,6-dideoxy-4-o-(2,6-dideoxy-3-c-methyl-4-o-(3-methylbutanoyl)-alpha-l-ribo-hexopyranosyl)-3-(dimethylamino)-beta-d-glucopyranosyl)oxy)-16-ethyl-5,9,13-tri |
3-acetyl-4''-isovaleryltylosin |
tylvalosin |
9t02s42wqo , |
tylvalosin [usan:inn] |
tylosin acetate isovalerate |
tylvalosin (ema epar: veterinary) |
tylosin acetate isovalerte |
CHEMBL2103834 |
tylosin 3-acetate 4b-(3-methylbutanoate) |
tylvalosin [usan] |
tylvalosin [mi] |
tylvalosin [green book] |
tylvalosin [inn] |
tylosin acetate isovalerte [jan] |
KCJJINQANFZSAM-HZDSEHBESA-N |
3-acetyl-4-isovaleryltylosin |
DB11554 |
DTXSID901016510 , |
NCGC00510884-01 |
Q27273124 |
aivlosin 17% |
tylvalosinum |
tylvalosine |
tilvalosina |
dtxcid301474699 |
Research Excerpts
Overview
Tylvalosin (TVN) is a water soluble macrolide used in swine production to treat enteric, respiratory, and arthritic pathogens. It is supposed to possess an immunosuppressive effect.
Actions
Tylvalosin tartrate can inhibit PRRSV proliferation in a dose-dependent manner, causing more than 90% proliferation reduction at 40 µg/mL.
Excerpt | Reference | Relevance |
---|---|---|
"Tylvalosin tartrate can inhibit PRRSV proliferation in a dose-dependent manner, causing more than 90% proliferation reduction at 40 µg/mL." | ( Evaluating anti-viral effect of Tylvalosin tartrate on porcine reproductive and respiratory syndrome virus and analyzing the related gene regulation by transcriptomics. Dai, Y; Ma, N; Ma, X; Sun, S; Sun, W; Tang, X; Wan, J; Wang, C; Wu, W; Xu, R; Yang, Q; Zhou, L; Zhu, G, 2023) | 1.92 |
"Tylvalosin tartrate can inhibit PRRSV proliferation in vitro in a dose-dependent manner. " | ( Evaluating anti-viral effect of Tylvalosin tartrate on porcine reproductive and respiratory syndrome virus and analyzing the related gene regulation by transcriptomics. Dai, Y; Ma, N; Ma, X; Sun, S; Sun, W; Tang, X; Wan, J; Wang, C; Wu, W; Xu, R; Yang, Q; Zhou, L; Zhu, G, 2023) | 2.64 |
Treatment
Tylvalosin treatment significantly reduced the level of L intracellularis infection. Almost half of the treated pigs were IHC-negative compared with 3.3 per cent of the untreated pigs.
Excerpt | Reference | Relevance |
---|---|---|
"Tylvalosin treatment markedly decreased IL-8, IL-6, IL-1β, PGE2, TNF-α and NO levels in vitro and in vivo." | ( Tylvalosin exhibits anti-inflammatory property and attenuates acute lung injury in different models possibly through suppression of NF-κB activation. Chen, W; Fu, L; Gao, J; Hou, S; Jia, H; Lai, Z; Liang, L; Shi, L; Tang, X; Yuan, W; Zhang, H; Zhang, K; Zhang, M; Zhang, W; Zhao, X; Zhao, Z, 2014) | 2.57 |
"The tylvalosin treatment significantly reduced the level of L intracellularis infection; almost half of the treated pigs were IHC-negative compared with 3.3 per cent of the untreated pigs." | ( Use of tylvalosin-medicated feed to control porcine proliferative enteropathy. Blumer, MA; da Costa Cruz, EC; França, SA; Guedes, RM; Machado, GS, 2009) | 1.29 |
Research
Studies (22)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (13.64) | 18.7374 |
1990's | 2 (9.09) | 18.2507 |
2000's | 1 (4.55) | 29.6817 |
2010's | 13 (59.09) | 24.3611 |
2020's | 3 (13.64) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 43.25
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (43.25) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 6 (26.09%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 17 (73.91%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |